Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Claudia Zylberberg

The Power List 2020 – Advanced Medicine


Chief Executive Officer at Akron Biotechnology

Zylberberg is concerned about the lack of closed or automated systems in cell and gene therapy. “The closing of systems will provide opportunities to manufacture in different environments, such as hospitals, and will enhance the capability to scale-out many of these autologous therapies. Right now, you would need a CMO to manufacture them, but a closed system would allow you to manufacture anywhere. The logistics, globally, of these therapies is also one of the biggest pieces of the puzzle.” Akron has responded to the COVID-19 epidemic by offering its biomolecules, such as interferons and other novel formulations, to be further investigated. “These will hopefully be used to create solutions for early stages of infection and advance initiatives that we’ve proposed both independently and in collaboration with others.”


Part of the Power List 2020

Find out more

Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.

Go to The Power List 2020

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register